Removing lung blood clots with the AlphaVac mechanical aspiration device

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study uses percutaneous mechanical aspiration thrombectomy with the AlphaVac MMA F1885 System to remove pulmonary artery clots in adults with CTPA-proven acute pulmonary embolism of ≤14 days. Eligible participants have evidence of right ventricular strain (RV/LV ≥1.0) and elevated troponin, plus clinical signs such as tachycardia, low-normal blood pressure, low oxygen levels, or known heart failure. The study will track procedure safety, immediate efficacy in clot removal and right-heart metrics, and longer-term functional outcomes. Patients with contraindications to therapeutic anticoagulation or significant comorbidities limiting life expectancy are excluded.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Symptomatic, CTPA-proven acute PE with a maximum duration of symptoms of 14 days, showing a filling defect in at least one main or proximal lobar pulmonary artery
* RV/LV diameter ratio ≥ 1.0 assessed by CTPA
* Serum troponin levels above upper limit of normal as per hospital policy
* ≥ 18 years of age
* At least one of the following:

  1. Electrocardiogram (ECG)-documented tachycardia with heart rate ≥ 100 BPM, not due to hypovolemia, arrhythmia or sepsis
  2. Systolic blood pressure ≤ 110mmHg for at least 15 minutes
  3. Respiratory rate \> 20 breaths per minuted. Oxygen saturation on pulse oximetry (SpO2) \< 90% (or partial arterial oxygen pressure \< 60 mmHg) at rest while breathing room air
  4. Known history of heart failure
* Willing and able to provide written informed consent prior to receiving study specific procedures.

Exclusion Criteria:

* A contraindication to therapeutic anticoagulation
* Any comorbid diagnosis consistent with a life expectancy of less than 1 year (e.g., stage 4 cancer)
* Known serious, uncontrolled sensitivity to radiographic agents
* Cardiac arrest within last 14 days without documented evidence of recovery of conscious level to Glasgow Coma Scale \>12
* Indication for ECMO
* Pregnant or breastfeeding
* Participation in another investigational drug or device study that study may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies.
* Other medical, social, or psychological conditions that, in the opinion of the Investigator, precludes the patient from appropriate consent, could limit the patient's ability to participate in the study, including compliance with follow- up requirements, or that could impact the scientific integrity of the study.
* History of congenital or acquired bleeding disorder predisposing to hemorrhagic state
* Platelet count \< 100,000/μL
* Any advanced reperfusion therapy for pulmonary embolism within 30 days of the index procedure (e.g lysis, surgery, catheter intervention)
* A known clot in transit
* IVC filter
* A do not resuscitate limitation at inclusion in the study
* Deprived of liberty or under court protection

Where it's running

• Poznan University of Medical Sciences
  Poznan, Poland Recruiting

Study contacts

• Principal investigator: Andrew Sharp — University College Dublin, Rep. of Ireland
• Study coordinator: Mitch Vanderpoll
• Email: mvanderpoll@angiodynamics.com
• Phone: +447790921819

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TRiP-cast score test in adults with acute lower-limb injuries requiring immobilization

  This study tests whether the TRiP(cast) score can predict risk of blood clots in adults with acute lower-limb injuries treated as outpatients.

  Recruiting University of Monastir · Monastir · NCT07863115

• Prognostic value of the 2026 AHA/ACC PE classification in ED patients with acute PE

  This study tests whether the 2026 AHA/ACC five-category PE classification helps predict 30-day major adverse pulmonary embolism events in adults with acute PE presenting to the ED.

  Recruiting Marmara University Pendik Training and Research Hospital · Istanbul · NCT07805616

• Right heart dysfunction in acute pulmonary embolism: can echocardiography help predict risk

  This study tests whether transthoracic echocardiography can identify right ventricular dysfunction in adults with acute pulmonary embolism to help gauge risk.

  Recruiting Sohag University · Sohag and 1 other locations · NCT07647497

• Aspiration thrombectomy with the Symphony or Prodigy devices

  This project will try the Symphony and Prodigy aspiration thrombectomy devices to remove arterial, venous, or pulmonary blood clots in adults.

  Recruiting at 13 sites Imperative Care, Inc. · Huntsville, Alabama and 12 other locations · NCT07350499

• PERC and YEARS approaches for diagnosing pulmonary embolism in the emergency department.

  This project will test whether using the PERC score and the YEARS algorithm helps emergency doctors decide which adults need D-dimer blood tests or chest CT scans to diagnose pulmonary embolism.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07313501

• Reperfusion options for acute pulmonary embolism

  This project will try catheter-directed interventions or systemic thrombolysis in adults with acute pulmonary embolism to see which approach leads to better outcomes.

  Recruiting at 12 sites Sahlgrenska University Hospital · Aarhus and 12 other locations · NCT07003646

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.